



PRESS RELEASE - FOR IMMEDIATE RELEASE

IntegraGen Announces Exclusive Licensing Agreement with The John Hopkins University and Massachusetts General Hospital for Autism Gene

EVRY (FRANCE) - APRIL 11, 2011 - IntegraGen, a French biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today that it has entered into an exclusive licensing agreement with The Johns Hopkins University and Massachusetts General Hospital to commercialize genetic tests that identify children at risk for autism which include a mutation to the Jumonji, AT Rich Interactive Domain 2 (JARID2) gene. Researchers at The Johns Hopkins University School of Medicine, Massachusetts General Hospital and IntegraGen have demonstrated that a specific mutation to this gene, known as a single-nucleotide polymorphism (SNP), is found in individuals with autism. IntegraGen has recently reported that the risk of autism is increased in children who have older siblings diagnosed with autism when this mutation of the JARID2 gene is found in combination with autism-related point mutations (SNPs) on other genes.

"This licensing agreement increases IntegraGen's exclusive access to genetic markers which have been shown to be associated with autism," stated Dr. Bernard Courtieu, CEO of IntegraGen, SA. "We believe that developing tests which include this and other genetic markers will permit the earlier identification of children at risk of autism and allow for more timely diagnosis and initiation of clinical intervention strategies for these children."

IntegraGen's corporate headquarters is located in Evry, France where it focuses on gene discovery and providing state of the art genotyping services to the research community through the Company's Genetic Services Business. The Company also has a U.S. subsidiary located in Cambridge, Massachusetts. IntegraGen owns intellectual property in the fields of autism and oncology and has focused efforts on understanding the role of common genetic variants as markers of an increased risk of autism. The Company has recently licensed autism-related intellectual property to Transgenomic, Inc., in the U.S. whose clinical molecular laboratory developed and offers the ARISK Familial Autism Panel (www.arisktest.com), a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder.

ABOUT INTEGRAGEN

IntegraGen (www.integragen.com) is a biotechnology company dedicated to gene discovery with the goal of developing molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen, and its wholly owned U.S. subsidiary IntegraGen, Inc., are focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen's Genetic Services Business, based in Evry, France, also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on autism and oncology, IntegraGen's core strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

CONTACT INFORMATION

INTEGRAGEN

Bernard Courtieu
Chief Executive Officer
Contact@integragen.com
Phone: +33 (0)1 60 91 09 00

Patrick Court
Chief Financial Officer
Contact@integragen.com
Phone: +33 (0)1 60 91 09 09

LT VALUE - INVESTOR RELATIONS AND CORPORATE COMMUNICATION

Investor Relations: Nancy Levain / Maryline Jarnoux-Sorin
nancy.levain@ltvalue.com / maryline.jarnoux-sorin@ltvalue.com
Phone: +33 (0)1 44 50 39 30 - +33 (0)6 72 28 91 44

Media Relations: Antoinette Darpy
antoinette.darpy@ltvalue.com
Phone: +33 (0)6 72 95 07 92